Myriad Corporate Presentation
Myriad Annual Report 2018

News Releases | Subscribe

February 14, 2020

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it is presenting new data at the American Society of Clinical Oncology Genitouranary Cancer Symposium in San Francisco, California.

Read More

February 12, 2020

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m.

Read More

February 11, 2020

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice ®

Read More

February 6, 2020

Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results

Total Second-Quarter Revenues of $195.1 Million Second-Quarter Diluted EPS of ($0.11) and Adjusted EPS of $0.23 SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

January 30, 2020

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

SALT LAKE CITY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal second-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

November 4, 2019

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

Total First-Quarter Revenues of $186.3 Million Excluding Out-of-Period Adjustments Revenue Would Have Been $197.5 Million First-Quarter Diluted EPS of ($0.28) and Adjusted EPS of $0.08 SALT LAKE CITY, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”),

Read More

February 12, 2020

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m.

Read More

February 6, 2020

Myriad Announces Leadership Transition

R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO Mark C. Capone Resigns, Effective Immediately SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine,

Read More

January 30, 2020

Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

SALT LAKE CITY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal second-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

February 14, 2020

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it is presenting new data at the American Society of Clinical Oncology Genitouranary Cancer Symposium in San Francisco, California.

Read More

February 11, 2020

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice ®

Read More

January 22, 2020

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice ®

Read More

February 14, 2020

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy

SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it is presenting new data at the American Society of Clinical Oncology Genitouranary Cancer Symposium in San Francisco, California.

Read More

February 11, 2020

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

SALT LAKE CITY, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice ®

Read More

January 22, 2020

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice ®

Read More